{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:55Z","timestamp":1792451755556,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor \u03b1 (FR\u03b1). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>SORAYA enrolled FR\u03b1-high patients with PROC who had received one to three prior therapies, including required bevacizumab. The primary end point was confirmed objective response rate (ORR) by investigator; duration of response was the key secondary end point.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>One hundred six patients were enrolled; 105 were evaluable for efficacy. All patients had received prior bevacizumab, 51% had three prior lines of therapy, and 48% received a prior poly ADP-ribose polymerase inhibitor. Median follow-up was 13.4 months. ORR was 32.4% (95% CI, 23.6 to 42.2), including five complete and 29 partial responses. The median duration of response was 6.9 months (95% CI, 5.6 to 9.7). In patients with one to two priors, the ORR by investigator was 35.3% (95% CI, 22.4 to 49.9) and in patients with three priors was 30.2% (95% CI, 18.3 to 44.3). The ORR by investigator was 38.0% (95% CI, 24.7 to 52.8) in patients with prior poly ADP-ribose polymerase inhibitor exposure and 27.5% (95% CI, 15.9 to 41.7) in those without. The most common treatment-related adverse events (all grade and grade 3-4) were blurred vision (41% and 6%), keratopathy (29% and 9%), and nausea (29% and 0%). Treatment-related adverse events led to dose delays, reductions, and discontinuations in 33%, 20%, and 9% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>MIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FR\u03b1-high PROC who had received up to three prior therapies, including bevacizumab, representing an important advance for this biomarker-selected population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.22.01900","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T16:00:14Z","timestamp":1675094414000},"page":"2436-2445","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":388,"title":["Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct04296890","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-6992","authenticated-orcid":false,"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[{"name":"Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-2633","authenticated-orcid":false,"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-2799","authenticated-orcid":false,"given":"Andrew","family":"Dean","sequence":"additional","affiliation":[{"name":"WA Medical Oncology St John of God Subiaco Hospital, Subiaco, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8897-9430","authenticated-orcid":false,"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[{"name":"Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-715X","authenticated-orcid":false,"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"European Institute of Oncology IRCCS, Milan, Italy"},{"name":"University of Milan-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-721X","authenticated-orcid":false,"given":"Toon","family":"Van Gorp","sequence":"additional","affiliation":[{"name":"University Hospital of Leuven, Leuven Cancer Institute, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0720-2719","authenticated-orcid":false,"given":"Jason A.","family":"Konner","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-8115","authenticated-orcid":false,"given":"Margarita Romeo","family":"Marin","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia\/Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-5005","authenticated-orcid":false,"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[{"name":"Ev. Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conleth G.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Bon Secours Hospital and Clinical Trials, Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuzhou","family":"Wang","sequence":"additional","affiliation":[{"name":"ImmunoGen Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Noble","sequence":"additional","affiliation":[{"name":"ImmunoGen Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Esteves","sequence":"additional","affiliation":[{"name":"ImmunoGen Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Method","sequence":"additional","affiliation":[{"name":"ImmunoGen Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"US Oncology Research, Texas Oncology, The Woodlands, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2016.626"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0047"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00188-5"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6735"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.05.016"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181daaf59"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8911"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8082"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"b13","volume-title":"AVASTIN [Package Insert]","author":"Genentech","year":"2016"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.032"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00334"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9589"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001219"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"b21","first-page":"3396","volume":"52","author":"Weitman SD","year":"1992","journal-title":"Cancer Res"},{"key":"b22","first-page":"118","volume":"4","author":"Lutz RJ","year":"2015","journal-title":"Transl Cancer Res"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006292"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.10.063"},{"key":"b25","first-page":"3869","volume":"61","author":"Hough CD","year":"2001","journal-title":"Cancer Res"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv250"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2004.12.026"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.11.010"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0459"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"b33","author":"Moore KN","journal-title":"J Clin Onco 38, 2020"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2474"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2012.10.003"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182049273"},{"key":"b40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30736"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.01900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T18:00:46Z","timestamp":1682532046000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.01900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":40,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,5,1]]}},"alternative-id":["10.1200\/JCO.22.01900"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.01900","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"2022-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}